Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin, which reversibly binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation. It exhibits primarily bacteriostatic activity against susceptible gram-positive cocci and anaerobes.
Reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting peptide bond formation and protein synthesis. May also act as a bacterial protein synthesis inhibitor by dissociating ribosomes.
Clindamycin 600-2700 mg/day IV divided every 6-8 hours. For severe infections, up to 4800 mg/day IV may be given.
Adult: 300-600 mg IV every 6-8 hours, up to 2.7 g/day in 3-4 divided doses for severe infections.
None Documented
None Documented
The terminal elimination half-life is approximately 2.4-3.0 hours in adults with normal renal and hepatic function; prolonged to 3-6 hours in hepatic impairment and up to 8-14 hours in severe hepatic disease.
The terminal elimination half-life is approximately 2.4 hours in adults with normal renal function, but increases to 3-5 hours in patients with severe hepatic impairment. Renal impairment has minimal effect. In neonates, half-life may be prolonged (up to 8-12 hours).
Clindamycin is primarily eliminated via hepatic metabolism; approximately 10% is excreted unchanged in urine, 3.6% in feces, and the remainder as inactive metabolites in bile and urine.
Clindamycin is primarily excreted via bile and feces (approximately 90% as metabolites), with renal elimination accounting for about 10% (parent drug and N-demethylated metabolite). Less than 1% is excreted unchanged in urine.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic